Respiratory Syncytial Virus Prevention within Reach: The Vaccine and Monoclonal Antibody Landscape

Simple item page
dc.contributor.authorNatalie I. Mazur, MD
dc.contributor.authorJonne Terstappen, MD
dc.contributor.authorRanju Baral, PhD
dc.contributor.authorAzucena Bardají, PhD
dc.contributor.authorPhilippe Beutels, PhD
dc.contributor.authorUrsula J. Buchholz, PhD
dc.contributor.authorCheryl Cohen, PhD
dc.contributor.authorJames E. Crowe Jr., MD
dc.contributor.authorClare L. Cutland, PhD
dc.contributor.authorLinda Eckert, MD
dc.contributor.authorDaniel Feikin, MD
dc.contributor.authorTiffany Fitzpatrick, PhD
dc.contributor.authorYouyi Fong, PhD
dc.contributor.authorBarney Graham, PhD
dc.contributor.authorTerho Heikkinen, PhD
dc.contributor.authorDeborah Higgins, BSc
dc.contributor.authorSiddhivinayak Hirve, MD
dc.contributor.authorKeith Klugman, PhD
dc.contributor.authorLeyla Kragten-Tabatabaie, PhD
dc.contributor.authorPhilippe Lemey, PhD
dc.contributor.authorRomina Libster, MD
dc.contributor.authorYvette Löwensteyn, MD
dc.contributor.authorAsuncion Mejias, PhD
dc.contributor.authorFlor M. Munoz, MD
dc.contributor.authorPatrick K. Munywoki, PhD
dc.contributor.authorLawrence Mwananyanda, MD
dc.contributor.authorHarish Nair, PhD
dc.contributor.authorMarta C. Nunes, PhD
dc.contributor.authorOctavio Ramilo, PhD
dc.contributor.authorPeter Richmond, MD
dc.contributor.authorTracy J. Ruckwardt, PhD
dc.contributor.authorCharles Sande, PhD
dc.contributor.authorPadmini Srikantiah, MD
dc.contributor.authorNaveen Thacker, MD
dc.contributor.authorKody A. Waldstein, MSc
dc.contributor.authorDan Weinberger, PhD
dc.contributor.authorJoanne Wildenbeest, PhD
dc.contributor.authorDexter Wiseman, MD
dc.contributor.authorHeather J Zar, PhD
dc.contributor.authorMaria Zambon, PhD
dc.contributor.authorLouis Bont, PhD
dc.date.accessioned2024-02-26T13:09:00Z
dc.date.available2024-02-26T13:09:00Z
dc.date.issued2023-01-23
dc.description.abstractRespiratory syncytial virus (RSV) is the second most common cause of infant mortality and an important cause of morbidity and mortality in older adults. Efforts to develop an RSV vaccine or immunoprophylaxis remain highly active. Thirty-three RSV prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particlebased, live-attenuated, chimeric, and nucleic acid in addition to monoclonal antibodies (mAbs). Eight candidates are in phase III clinical trials. Understanding the epitopes targeted by highly neutralizing antibodies has resulted in a shift from empirical to rational and structure-based vaccine and mAb design. An extended half-life mAb for all infants is likely within one year of regulatory approval for high income countries. Live-attenuated vaccines are in development for older infants. Subunit vaccines are in late-stage trials for pregnant women to protect infants, while vector, subunit and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of an RSV vaccine globally. This review gives an overview of RSV vaccines and mAbs in clinical development highlighting different target populations, antigens, and latest trial results.
dc.description.librarianPM2023
dc.facultyFaculty of Health Sciences
dc.identifier.urihttps://hdl.handle.net/10539/37718
dc.language.isoen
dc.schoolPublic Health
dc.subjectrespiratory syncytial virus; vaccines
dc.titleRespiratory Syncytial Virus Prevention within Reach: The Vaccine and Monoclonal Antibody Landscape
dc.typeArticle
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
nihms-1830389.pdf
Size:
1.37 MB
Format:
Adobe Portable Document Format
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
2.43 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
SA-MRC/Wits Agincourt Unit (Research Outputs/Publications)